Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by quest13on Nov 05, 2020 9:10am
197 Views
Post# 31841133

RE:cost basis

RE:cost basisI have pointed out the valuation FAQ for Zenith Capital Corp. Or as I think of the spin out from RVX in 2103, as ZCC or my broker assigns a non existent symbol of ZENE for reporting on my account. My broker has not been derailed by the ZHCLF screwup.

Complicating the situation ZCC has set up a 100% owned subsidiary ZEL or Zenith Epigenetics Limited. It was/is my opinion that the setup of ZEL was to allow ZCC to set up ZEL for sale to a new partner interested in ZEL and for tax efficiency to allow ZCC to, prior to a sale of ZEL, do another action like the the 2013 deal by which we all got ZCC shares tax efficiently. without any immediate tax consequences.

I believe the intent was to distribute shares of ZEL effectively tax free on the split of ZCC shares in our hands to shares of ZCC and ZEL. This would leave us in a position to take a large capital gain on the 3rd party sale of ZEL to a purchaser.

i aso believe that the ZHCLF issue is just a general screwup by brokers which has no effect on our shareholdings and I have no idea what it is.

Bullboard Posts